📅 28 June 2026 | EarnFree.in | Sector Analysis
While Nifty Metal collapsed 4.3% and IT fell 4% this week, one sector quietly delivered India’s best weekly stock market performance: Nifty Pharma rose 2.8% — powered by Citi and Nomura upgrades on Cipla and Dr Reddy’s, and driven by the structural tailwind of a US-India trade deal reducing pharma tariffs from 50% to 18%. With crude-driven inflation cooling and RBI rate cuts on the horizon, pharma’s defensive-plus-growth profile makes it the standout sector for Q3 2026.
💊 Nifty Pharma — Weekly Performance (Week ending June 25)
| Sector | Weekly Return |
|---|---|
| 🟢 Nifty Pharma | +2.8% (TOP performer) |
| 🟢 Nifty Private Bank | +1.0% |
| 🟢 Nifty Auto | +0.9% |
| 🟢 Nifty Realty | +0.7% |
| 🟡 Nifty Bank | +0.4% |
| 🔴 Nifty Oil & Gas | -1.4% |
| 🔴 Nifty PSU Bank | -1.5% |
| 🔴 Nifty Consumer Durables | -2.8% |
| 🔴 Nifty IT | -4.0% |
| 🔴 Nifty Metal | -4.3% (WORST performer) |
💊 Why Cipla and Dr Reddy’s Are Getting Analyst Love
Citi and Nomura both published positive notes on Cipla and Dr Reddy’s this week. The core thesis: Indian pharma companies are the biggest beneficiaries of the US-India trade deal reducing tariffs from 50% to 18%. The US is India’s largest pharma export market — worth $8.7 billion annually. At 18% tariffs vs 50%, Indian generic drug makers get a massive margin expansion. Additionally, the FDA approval pipeline for Cipla’s US generics division is accelerating, with 3 new ANDA approvals expected in Q2 FY27.
🎯 Top Pharma Stocks to Watch — July 2026
- 💊 Cipla (NSE: CIPLA): Citi upgrade — US generics recovery, branded India business strong, respiratory franchise growing
- 💊 Dr Reddy’s (NSE: DRREDDY): Nomura positive — biosimilars pipeline the key catalyst, Russia business stabilising
- 💊 Sun Pharma: Largest Indian pharma — dermatology specialty portfolio + US specialty growing
- 💊 Divi’s Laboratories: API manufacturer — crude ↓ = input cost relief + US-India tariff normalisation
- 💊 Aurobindo Pharma: Deep US generics exposure — most leveraged to tariff reduction
⚠️ Disclaimer: This article is for informational and educational purposes only. It is not SEBI-registered investment advice. Stock prices are subject to market risk. Please consult a certified financial advisor before investing.
